OCE-205, a selective V1a receptor mixed agonist-antagonist, for the treatment of hepatorenal syndrome-acute kidney injury: A phase 2 randomized trial.

Journal:

Hepatology

Published:

2026-04-09

DOI:

10.1097/hep.0000000000001765

Affiliations:

9

Authors:

7

Go to article

Institutions	Authors	Share
Ocelot Bio, United States of America (USA)	2.000000	0.29
Columbia University Irving Medical Center (CUIMC), CU, United States of America (USA)	1.000000	0.14
Massachusetts General Hospital (MGH), United States of America (USA)	1.000000	0.14
Stanford University, United States of America (USA)	1.000000	0.14
Michael Garron Hospital (MGH), Canada	1.000000	0.14
Rutgers Health, United States of America (USA)	0.333333	0.05
University Hospital Newark, NJ, United States of America (USA)	0.333333	0.05
NYU Langone Health, United States of America (USA)	0.333333	0.05

Interested in Clinical Sciences?